000110736 001__ 110736 000110736 005__ 20230519145623.0 000110736 0247_ $$2doi$$a10.3390/biomedicines9111729 000110736 0248_ $$2sideral$$a127209 000110736 037__ $$aART-2021-127209 000110736 041__ $$aeng 000110736 100__ $$aSanz, L. 000110736 245__ $$aAntibody-based immunotoxins for colorectal cancer therapy 000110736 260__ $$c2021 000110736 5060_ $$aAccess copy available to the general public$$fUnrestricted 000110736 5203_ $$aMonoclonal antibodies (mAbs) are included among the treatment options for advanced colorectal cancer (CRC). However, while these mAbs effectively target cancer cells, they may have limited clinical activity. A strategy to improve their therapeutic potential is arming them with a toxic payload. Immunotoxins (ITX) combining the cell-killing ability of a toxin with the specificity of a mAb constitute a promising strategy for CRC therapy. However, several important challenges in optimizing ITX remain, including suboptimal pharmacokinetics and especially the immunogenicity of the toxin moiety. Nonetheless, ongoing research is working to solve these limitations and expand CRC patients’ therapeutic armory. In this review, we provide a comprehensive overview of targets and toxins employed in the design of ITX for CRC and highlight a wide selection of ITX tested in CRC patients as well as preclinical candidates. © 2021 by the authors. Licensee MDPI, Basel, Switzerland. 000110736 536__ $$9info:eu-repo/grantAgreement/ES/DGA/B31-20R 000110736 540__ $$9info:eu-repo/semantics/openAccess$$aby$$uhttp://creativecommons.org/licenses/by/3.0/es/ 000110736 590__ $$a4.757$$b2021 000110736 592__ $$a0.874$$b2021 000110736 594__ $$a3.0$$b2021 000110736 591__ $$aBIOCHEMISTRY & MOLECULAR BIOLOGY$$b121 / 297 = 0.407$$c2021$$dQ2$$eT2 000110736 593__ $$aMedicine (miscellaneous)$$c2021$$dQ1 000110736 591__ $$aPHARMACOLOGY & PHARMACY$$b87 / 279 = 0.312$$c2021$$dQ2$$eT1 000110736 593__ $$aBiochemistry, Genetics and Molecular Biology (miscellaneous)$$c2021$$dQ1 000110736 591__ $$aMEDICINE, RESEARCH & EXPERIMENTAL$$b62 / 140 = 0.443$$c2021$$dQ2$$eT2 000110736 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/publishedVersion 000110736 700__ $$aIbáñez-Pérez, R.$$uUniversidad de Zaragoza 000110736 700__ $$0(orcid)0000-0002-1657-4792$$aGuerrero-Ochoa, P.$$uUniversidad de Zaragoza 000110736 700__ $$aLacadena, J. 000110736 700__ $$0(orcid)0000-0002-5175-8394$$aAnel, A.$$uUniversidad de Zaragoza 000110736 7102_ $$11002$$2060$$aUniversidad de Zaragoza$$bDpto. Bioq.Biolog.Mol. Celular$$cÁrea Bioquímica y Biolog.Mole. 000110736 7102_ $$11002$$2050$$aUniversidad de Zaragoza$$bDpto. Bioq.Biolog.Mol. Celular$$cÁrea Biología Celular 000110736 773__ $$g9, 11 (2021), 1729 [24 pp]$$tBiomedicines$$x2227-9059 000110736 8564_ $$s1022053$$uhttps://zaguan.unizar.es/record/110736/files/texto_completo.pdf$$yVersión publicada 000110736 8564_ $$s2773497$$uhttps://zaguan.unizar.es/record/110736/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada 000110736 909CO $$ooai:zaguan.unizar.es:110736$$particulos$$pdriver 000110736 951__ $$a2023-05-18-16:17:20 000110736 980__ $$aARTICLE